anti-PD1 Approved for Lung Cancer!

Anti-PD1, which is one of the more potent checkpoint blockade treatments with very mild side effects, has just been approved for lung cancer.

Anti-PD1 Immunotherapy in Hodgkin's Lymphoma: Clinical Trial Results (Dec 2014)

Hodgkin's Lymphoma anti-PD1 phase 1b clinical trial resultsAnti-PD1 treatments are showing tremendous results for Hodgkin's Lymphoma patients who have not responded to conventional treatments.

The results are coming out at the American Society of Hematology (ASH) conference, December 2014 and creating great excitement.


Giving Thanks 2014: My secret confession.

Keep Calm and Give ThanksHappy Thanksgiving to All!

Since my cancer diagnosis almost 7 years ago, I've encountered many people with cancer. The interesting thing is a large proportion of them have non-small cell lung cancer (NSCLC).

Anti-PD1 Immunotherapy in Lung Cancer: Video and Summary

This is an excellent video explaining immunotherapy in lung cancer, primarily focusing on anti-PD1.

This video was published November 4, 2014 by Global Resource for Advancing Cancer Education (GRACE).

Dr. Jack West (Swedish Cancer Center, Seattle) moderates this discussion with Dr. Julie Brahmer (John Hopkins, Baltimore) and Dr. Ben Creelan (Moffitt Cancer Center, Tampa).

Cryoablation: freezing + killing tumor with probes, creating an in-situ cancer vaccine

What is cryoablation?
Cryoablation is a physical modality to destroy tumor by freezing tumor with needle probes that are inserted into or immediately adjacent to a tumor.
What does the procedure involve?

Potential to enhance efficacy of checkpoint blockade

A patient was on Yervoy for many months but progressed. A painful spinal lung met developed. The clinicians (Dr. James Allison's colleagues at Memorial Sloan in New York) decided to irradiate for pain relief. Amazingly, one month later, when Yervoy was resumed, all other progressing tumors regressed (not just the sole irradiated tumor). They documented this exciting finding in a case report.

Checkpoint blockade - the hottest thing in conventional cancer immunotherapy


Back in 2009, when I began my quest to understand Coley's Toxins, my wife's boss at the university connected us with a very special human being. His name was Dr. Lloyd Old, once former Vice President at Memorial Sloan Kettering Cancer Center, but in recent years before his passing away, fully dedicated chief of the Ludwig institute for Cancer Research (or LICR). LICR is a well funded non-profit research organization that sponsors and nurtures a large worldwide collaborative of leading researchers in the field of cancer immunotherapy.

Cancer immunotherapy comes of age

A few days ago, I was scanning google scholar for the latest research on checkpoint blockade immunotherapy. I found a good paper that explains the current state cancer advances in the field of immunotherapy, including recent advances in checkpoint blockade:

Here's a link to that journal paper entitled "Cancer Immunotherapy comes of Age"

Embedded within the paper was the following important point:

Coley's Toxins

About Coley's Toxins

I'm not going to re-invent the wheel here. I'm going to refer you to the most palatable introduction to Coley's Toxins for the layman—a paid report written by Ralph Moss on his website ( It's a 100 page report but is quite inexpensive. For those of you who don't have the patience or time to read through that long report, you can check out Dr. Moss' shorter description of Coley's Toxins for free .

Syndicate content